Non-alcoholic steatohepatitis and animal models: understanding the human disease.
about
Ion Channels and Oxidative Stress as a Potential Link for the Diagnosis or Treatment of Liver DiseasesMolecular changes in hepatic metabolism and transport in cirrhosis and their functional importanceInflammasome-mediated dysbiosis regulates progression of NAFLD and obesityIn vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).High-frequency ultrasound imaging for longitudinal evaluation of non-alcoholic fatty liver disease progression in mice.The role of mitochondria in osteogenic, adipogenic and chondrogenic differentiation of mesenchymal stem cells.FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilizationSpecific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione.Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels.Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.Glycine N-methyltransferase deficiency affects Niemann-Pick type C2 protein stability and regulates hepatic cholesterol homeostasis.Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.Recent advances in the development of farnesoid X receptor agonistsFrom whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitationsSynergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK.Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine.Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosisHepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humansMelanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient miceNASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.The current state of knowledge of hepatic ischemia-reperfusion injury based on its study in experimental models.Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3.Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models.Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury.Animal models of in utero exposure to a high fat diet: a review.Alcoholic liver disease and exacerbation by malnutrition and infections: what animal models are currently available?Induction of cross-linking and silencing of Sp1 by transglutaminase during liver injury in ASH and NASH via different ER stress pathways.Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.Inhibitory effect of Ginkgo biloba extract on fatty liver: regulation of carnitine palmitoyltransferase 1a and fatty acid metabolism.Fatty liver oxidative events monitored by autofluorescence optical diagnosis: Comparison between subnormothermic machine perfusion and conventional cold storage preservation.Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis.Integrated autofluorescence characterization of a modified-diet liver model with accumulation of lipids and oxidative stress.A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis.Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice.Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice.Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.Protective effect of apricot (Prunus armeniaca L.) on hepatic steatosis and damage induced by carbon tetrachloride in Wistar rats.
P2860
Q26765808-14C4B4DD-D349-469C-A697-2AA128334994Q26769609-F012D187-D5AD-478D-B1AB-A4B8565D83A7Q28512778-BF4023FD-173F-4C1E-A0D8-07110C3F7E99Q30452333-301BE006-CE6F-454B-AF15-C6079A4B40DBQ30466289-9788643E-FD9E-444D-BA9C-01A35027765BQ33729045-7D257BA0-6BCD-4476-8982-4988A83B94DCQ33741191-5CD27E6B-8A6D-4B96-AD3B-8C4A094D75DAQ33824907-21FB570C-A0E6-4FF6-814D-37A158E72378Q33897826-2DBF2B89-3D54-4869-BB56-414917E05E35Q33906456-7E44967B-5475-4DF8-A4DD-26403A4B270AQ34103693-7CB1899B-C5D7-4F03-B5E6-8647F62CA51AQ34241720-7F8D00E2-2373-4984-94D4-5C470A4F7221Q34440771-3D2F31D5-0632-40E1-A156-19185BF160E8Q34464043-28BE85C5-9661-4124-A20E-4C12E8186E60Q34800989-867326AA-33CE-427F-BB1B-AF5DF955F449Q34981610-13DDD0C3-2B6B-41E9-9C0B-A91CDF0A40BBQ34990988-C4EDD1E9-493B-4BD3-B545-9D9D9DFC7C33Q35056710-B01FA8E5-40FB-4126-89BB-FC2DCA8E6F7AQ35070019-E1C2A15A-F98B-4D04-9C42-26A13024FF9FQ35474335-01303A16-84B0-4DEF-8071-8A4F788625DCQ35588868-334AC367-901D-4CAF-85DD-D608654090A4Q35931190-3743EFD4-ABC3-4F81-9AA3-18F8A9BBAA94Q35977888-1063B113-8E9C-47E8-A768-5D2547AC9A74Q36826832-0C1B7EEE-D8D7-4539-93C8-1DA7FF8A5C45Q37166770-54AF23A3-D95C-406A-BDA8-38680FB700C3Q37199958-D2DD3D2D-2025-4525-908E-66AA5B2F4292Q37492276-D67B92FC-0764-4039-9BE4-393B03725935Q37823647-F892037C-8A2F-4402-8CC3-01C6B1AAF1D1Q37869760-C2E6B388-ECA1-4404-B0A0-1B2F11551EB0Q38168505-B2613A1B-A5A7-4A50-8BBE-17D8D4F913ADQ39276367-7EB64B6A-F57D-4BB9-80B1-CE074275008CQ39569591-73311FE1-EB39-4E8B-A091-4E719BC3AA9DQ39659924-9E8BCC9D-2D98-4011-967E-6D07AD6F5515Q40514578-D205E259-0086-4426-BEC7-E07C0305587DQ41162120-BE946A23-DEFE-459A-AC63-0EAF4C9563BDQ41761865-BBC6E65C-5F63-41DC-852D-71BFBE0AF05CQ41841000-8989AFED-FB72-4276-AA5A-FA7D2B2F1865Q41911004-5644BF1F-0C32-47C6-A1A1-CB341D9B411BQ42369256-E17BD2A3-42FB-4211-A18E-5366594F6296Q43263202-DE84CA84-0287-429C-8B8D-D66A28B740D0
P2860
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
@en
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
@nl
type
label
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
@en
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
@nl
prefLabel
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
@en
Non-alcoholic steatohepatitis and animal models: understanding the human disease.
@nl
P2093
P1476
Non-alcoholic steatohepatitis and animal models: understanding the human disease
@en
P2093
José M Mato
Marta Varela-Rey
Nieves Embade
Shelly C Lu
P304
P356
10.1016/J.BIOCEL.2008.10.027
P577
2008-11-05T00:00:00Z